Amendment S.2512

This bill amends existing healthcare regulations to include continuous glucose monitoring systems and related diabetes supplies within the state's drug selection and coverage program. It defines these systems as devices that continuously sense and display blood glucose levels and explicitly lists components like sensors, transmitters, and delivery devices as eligible for selection. Under the new rules, the state commission must choose one generic and one brand-name version of these monitoring systems, just as it does for traditional medications. Once selected, these systems and their necessary parts would be covered without deductibles or co-insurance, and co-payments for brand-name options would be capped at $25 per 30-day supply. The legislation also expands the list of covered diabetes supplies to include items such as syringes, needles, and calibration strips, ensuring they are exempt from cost-sharing requirements.